An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…
eculizumab
Soliris (eculizumab) significantly reduced the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) over nearly three years, according to new data from the clinical trial PREVENTÂ and its extension study. Additional findings project that long-term Soliris treatment may reduce relapse risk over the course of…
Treatment with Soliris (eculizumab) does not increase the risk of infections or serious infections among people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the protein aquaporin-4 (AQP4), even in those receiving accompanying immunosuppressive therapies. Those were the findings from a post hoc analysis of…
The autoimmune biomarker CH50 was directly impacted by treatment with Soliris (eculizumab) in three people with neuromyelitis optica spectrum disorder (NMOSD), a case report has shown. According to researchers, this suggests that CH50 may be a useful…
Recent Posts
- Advocates join forces to create, celebrate World NMOSD Awareness Day
- With a compromised immune system, constant infections are my nemesis
- Approved NMOSD therapies better than rituximab at preventing relapses
- Embracing an opportunity for advocacy on Rare Disease Day
- Cognitive issues affect nearly 1 in 3 with NMOSD, study finds